glp 1 utilization trend GLP-1 Drug Market: the rapid growth of the diabetes and obesity drugs market Automated Diagnosis Verification of GLP-1
Description
The most common designs are observational studies
It acts as a bispecific molecule, combining GLP-1 receptor agonism with GIP receptor antagonism to promote weight loss
GLP-1 GLP-1 RybelsusSemaglutide
Adult people (18 years) with a diagnosis of obesity (body mass index30 kg/m2) or T2DM (ICD-10-CM: E11) between 2018 and 2024 were subdivided in two mutually exclusive cohorts: (1) GLP-1 RA Users
